De-Hong Wu

De-Hong Wu

Auto-generated profile, based on publicly available information

De-Hong Wu

Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
XLXi-Xi Li
Xi-Xi Li
JZJingdong Zhou
Jingdong Zhou
XWXiang-Mei Wen
Xiang-Mei Wen
TZTing-Juan Zhang
Ting-Juan Zhang
DWDe-Hong Wu
De-Hong Wu
JQJun Qian
Jun Qian
Background: Altered expression of the BCL-2 family member MCL-1 has been linked to the progression and outcome of various malignancies. Recently, MCL-1 inhibitor S63845 was reported to kill MCL-1-dependent cancer cells and has potential value in clinical application. Purpose: Herein, we reported MCL-1 expression pattern in Chinese de novo acute myeloid leukemia (AML) and its impact on prognosis and may provide theoretical basis for AML patients using MCL-1 inhibitor in clinics. Real-time quantitative PCR was carried out to detect the transcript of MCL-1 in AML patients. Results: MCL-1 expression was significantly up-regulated in AML compared with controls (P=0.042). We divided the patients into two groups (higher and lower expression of MCL-1) based on the median level. Among both non-acute promyelocytic leukemia (APL) and cytogenetically normal AML (CN-AML), patients with higher expression of MCL-1 correlated with lower complete remission (CR) rate (P=0.031 and 0.004, respectively) and shorter overall survival (OS) time (P=0.008 and 0.004, respectively) compared with those with lower expression of MCL-1. Meanwhile, Cox regression analyses revealed that overexpression of MCL-1 acted as an independent risk factor for OS in non-APL patients and CN-AML patients (P=0.011 and 0.045, respectively). In follow-up patients, MCL-1 expression level decreased after CR compared with newly diagnosis time (P=0.020) and increased after relapse (P=0.004). Conclusion: Our findings suggest that higher expression of MCL-1 predicts poor prognosis and can be used for disease monitoring.

18 November 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
PHPin‐Fang He
Pin‐Fang He
ZXZi-jun Xu
Zi-jun Xu
JZJingdong Zhou
Jingdong Zhou
XLXi‐Xi Li
Xi‐Xi Li
WZWei Zhang
Wei Zhang
JQJun Qian
Jun Qian

1 September 2017 in Oncotarget
Verified
Journal Article
Open access
JZJingdong Zhou
Jingdong Zhou
JMJichun Ma
Jichun Ma
TZTing-Juan Zhang
Ting-Juan Zhang
XLXi-Xi Li
Xi-Xi Li
WZWei Zhang
Wei Zhang
JQJun Qian
Jun Qian
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jing-Dong Zhou1, 3, *, Ji-Chun Ma2, 3, *, Ting-Juan Zhang1, 3, *, Xi-Xi Li1, 3, Wei Zhang1, 3, De-Hong Wu4, Xiang-Mei Wen2, 3, Zi-Jun Xu2, 3, Jiang Lin2, 3 and Jun Qian1, 3 1Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China 2Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China 3The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China 4Department of Hematology, The Third People’s Hospital of KunShan City, Suzhou, Jiangsu, People’s Republic of China *These authors have contributed equally to this work Correspondence to: Jun Qian, email: qianjun0007@hotmail.com Jiang Lin, email: linjiangmail@sina.com Keywords: ID2, expression, prognosis, TCGA, AML Received: June 22, 2017 Accepted: August 09, 2017 Published: September 01, 2017 ABSTRACT Dysregulation of ID proteins is a frequent event in various human cancers and has a direct role in cancer initiation, maintenance, progression and drug resistance. Our previous study has revealed ID1 expression and its prognostic value in acute myeloid leukemia (AML). Herein, we further reported ID2 expression and its clinical significance in AML. Real-time quantitative PCR was performed to detect ID2 transcript level in bone marrow mononuclear cells of 145 de novo AML patients. ID2 expression was significantly up-regulated in AML patients compared with controls. ID2 overexpression occurred with the highest frequency in poor karyotype (10/17, 59%), lower in intermediate karyotype (35/83, 42%), and the lowest in favorable karyotype (7/40, 18%). Moreover, high ID2 expression correlated with lower complete remission (CR) rate, shorter overall survival, and acted as an independent prognostic biomarker in whole-cohort AML and non-M3-AML patients. Importantly, the prognostic value of ID2 expression in AML was validated by The Cancer Genome Atlas (TCGA) data. In the follow-up of patients, ID2 expression at CR phase was decreased than at the time of diagnosis, and was increased again at the time of relapse. These findings demonstrated that bone marrow ID2 overexpression was a frequent event in AML patients, and predicts poor chemotherapy response and prognosis.

31 May 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DWDe-Hong Wu
De-Hong Wu
DYDong-Ming Yao
Dong-Ming Yao
LYLei Yang
Lei Yang
JMJichun Ma
Jichun Ma
XWXiang-Mei Wen
Xiang-Mei Wen
JQJun Qian
Jun Qian
Abnormal methylation of let-7a-3 has been found in various cancers and may consequently affect their survival. In this study, real-time quantitative methylation specific PCR (RQ-MSP) was used to determine the unmethylation level of let-7a-3 in 95 patients with myelodysplastic syndrome (MDS). The hypomethylation of let-7a-3 promoter was detected in 22 of 95 (23.2%) patients with MDS compared to 4.2% (1/24) of controls (p= 0.0419). Moreover, the frequency of let-7a-3 hypomethylation was higher in older patients (≥70 years) than in younger patients (<70 years). No significant difference was observed in distribution of WHO, IPSS, and cytogenetic classification. However, hypomethylated patients had significantly shorter overall survival than those without hypomethylation (p= 0.007). Moreover both Kaplan–Meier and Multivariate Cox analyses confirmed that let-7a-3 hypomethylation was an independent prognostic risk factor in cohorts of MDS patients with lower-risk disease. Our study suggested that let-7a-3 hypomethylation may predict poor outcome in MDS.

1 May 2018 in Pathology - Research and Practice
Verified
Journal Article
Closed access
XYXin-Yu Yao
Xin-Yu Yao
JZJingdong Zhou
Jingdong Zhou
JYJing Yang
Jing Yang
WZWei Zhang
Wei Zhang
JMJichun Ma
Jichun Ma
JLJiang Lin
Jiang Lin

13 December 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
DWDe‐Hong Wu
De‐Hong Wu
XZXiao‐Wen Zhu
Xiao‐Wen Zhu
XWXiang‐Mei Wen
Xiang‐Mei Wen
YZYing‐Ying Zhang
Ying‐Ying Zhang
JMJi‐Chun Ma
Ji‐Chun Ma
JQJun Qian
Jun Qian
Background: Previous studies have disclosed up‐regulation of MIR‐378 in acute myeloid leukemia (AML), and might consequently affect the outcome of the patients. Correspondingly, hypomethylation of MIR‐378 was also identified in AML, particularly for FAB‐M2 subtype with t(8;21) chromosomal translocation. Nevertheless, the methylation status of MIR‐378 has not been illustrated in myelodysplastic syndrome (MDS). Herein we designed to understand the methylation pattern of MIR‐378 involved in MDS and clinical interrelation thereof.Methods: Real‐time quantitative methylation‐specific PCR (RQ‐MSP) was performed to evaluate the methylation degree of MIR‐378 5’‐flanking region on bone marrow mononuclear cells collected from 95 de novo MDS patients. Five gene mutations (IDH1, IDH2, DNMT3A, U2AF1, and SF3B1) were detected by high‐resolution melting analysis to further evaluate the clinical relevance of hypomethylation of MIR‐378.Results: Unmethylated level of MIR‐378 5’‐flanking region was significantly higher in MDS patients than that in controls (p = .034). Hypomethylated MIR‐378 was identified in 20 of 95 (21%) cases with MDS. Male patients appeared to be more frequent to harbor MIR‐378 hypomethylation compared to female patients (15/55, 27.3% vs. 4/40, 10.0%, p = .04). There was no significant difference in age, white blood cell counts, platelet counts, hemoglobin concentration, and karyotypes between the patients with and without MIR‐378‐hypomethylation. Distinct distribution of five gene mutations was not observed in the two groups as well. However, MIR‐378‐hypomethylated patients had significantly shorter overall survival than those without MIR‐378 hypomethylation (p = .036). Moreover, among patients <60 years, hypomethylation of MIR‐378 was confirmed to be an independent adverse prognostic factor by both Kaplan–Meier and Multivariate Cox analyses.Conclusion: Hypomethylation of MIR‐378 5’‐flanking region is an adverse prognosticator in MDS, particularly in patients <60 years.